Pirtobrutinib, marketed under the brand name Jaypirca, is FDA approved. The FDA granted accelerated approval to Pirtobrutinib on January 27, 2023.

Transposon Reports Conclusive Data from Phase 2 Trial of TPN-101 Targeting C9orf72-Linked ALS and/or Frontotemporal Dementia.

Elacestrant was approved by the FDA on January 27, 2023, for the treatment of advanced or metastatic breast cancer in postmenopausal women and adult men.

Sage Therapeutics and Biogen Reveal Key Findings from Phase 2 KINETIC 2 Trial of SAGE-324 (BIIB124) for Essential Tremor Treatment.

The FDA approved Bexagliflozin under the brand name Brenzavvy on January 20, 2023.

Pfizer Inc. revealed encouraging topline outcomes from the Phase 3 AFFINE trial, which assesses giroctocogene fitelparvovec.

The FDA approved the combination of albuterol and budesonide under the brand name Airsupra on January 10, 2023.

This trial aims to assess the efficacy and safety of petosemtamab, a Biclonics targeting EGFR and LGR5.

Lecanemab, marketed under the brand name Leqembi, was granted accelerated approval by the FDA on January 6, 2023.

Jul 30th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Ublituximab, marketed under the brand name Briumvi, is a CD20 monoclonal antibody used in the treatment of multiple sclerosis (MS). Ublituximab was approved by the FDA on December 28, 2022.

Rhythm Pharmaceuticals Begins Dosing First Patients in Phase 2 Trial for Oral MC4R Agonist LB54640 Targeting Hypothalamic Obesity.